Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2026

Five new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended five medicines for approval at its April 2026 meeting.The committee recommended…, CHMP statistics Key figures from the April 2026 CHMP meeting are represented in the graphic below. , CHMP statistics Key figures from the April 2026 CHMP meeting are represented in the graphic below…, Positive recommendations on new medicines, Cenrifki INN tolebrutinib Marketing authorisation applicant Sanofi Winthrop Industrie Therapeutic indication Treatment of non-relapsing secondary progressive…, Itvisma INN onasemnogene abeparvovec Marketing authorisation applicant Novartis Europharm Limited Therapeuti